@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/PlanDefinition/RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients> a fhir:PlanDefinition ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients"] ; # 
  fhir:meta [
     fhir:profile ( [
       fhir:v "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation"^^xsd:anyURI ;
       fhir:link <https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation>
     ] )
  ] ; # 
  fhir:text [
     fhir:status [ fhir:v "generated" ] ;
     fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: PlanDefinition RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients</b></p><a name=\"RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients\"> </a><a name=\"hcRecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients\"> </a><a name=\"RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients-en-US\"> </a><p><b>url</b>: <a href=\"PlanDefinition-RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients.html\">PlanDefinition Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</a></p><p><b>version</b>: 1.0</p><p><b>name</b>: 17 - Therapeutic Anticoagulation</p><p><b>title</b>: Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type workflow-definition}\">Workflow Definition</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>date</b>: 2022-02-14</p><p><b>publisher</b>: Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)</p><p><b>description</b>: </p><div><p>Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden.</p>\n</div><h3>Actions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Title</b></td><td><b>Description</b></td><td><b>Code</b></td><td><b>Definition[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Therapeutic_Anticoagulation_No_Renal_Function_Impairment</td><td><div><p>Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)</p>\n</div></td><td><span title=\"Codes:{http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process guideline-based-care}\">Guideline-based Care</span></td><td><a href=\"PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html\">Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></td></tr></table></div>"
  ] ; # 
  fhir:extension ( [
     fhir:url [ fhir:v "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability"^^xsd:anyURI ] ;
     fhir:value [ fhir:v "computable" ]
  ] [
     fhir:url [ fhir:v "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel"^^xsd:anyURI ] ;
     fhir:value [ fhir:v "structured" ]
  ] [
     fhir:extension ( [
       fhir:url [ fhir:v "method"^^xsd:anyURI ] ;
       fhir:value [
         a fhir:CodeableConcept ;
         fhir:coding ( [
           fhir:system [ fhir:v "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "exactly" ]
         ] )
       ]
     ] [
       fhir:url [ fhir:v "threshold"^^xsd:anyURI ] ;
       fhir:value [ fhir:v "1"^^xsd:positiveInteger ]
     ] ) ;
     fhir:url [ fhir:v "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method"^^xsd:anyURI ]
  ] ) ; # 
  fhir:url [ fhir:v "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "1.0"] ; # 
  fhir:name [ fhir:v "17 - Therapeutic Anticoagulation"] ; # 
  fhir:title [ fhir:v "Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients"] ; # 
  fhir:type [
     fhir:coding ( [
       fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/plan-definition-type"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "workflow-definition" ]
     ] )
  ] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v "true"^^xsd:boolean] ; # 
  fhir:date [ fhir:v "2022-02-14"^^xsd:date] ; # 
  fhir:publisher [ fhir:v "Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)"] ; # 
  fhir:description [ fhir:v "Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden."] ; # 
  fhir:action ( [
     fhir:title [ fhir:v "Therapeutic_Anticoagulation_No_Renal_Function_Impairment" ] ;
     fhir:description [ fhir:v "Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)" ] ;
     fhir:code [
       fhir:coding ( [
         fhir:system [ fhir:v "http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "guideline-based-care" ]
       ] )
     ] ;
     fhir:definition [
       fhir:v "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation"^^xsd:anyURI ;
       fhir:link <https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation>
     ]
  ] ) . # 

# -------------------------------------------------------------------------------------

